BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang YX, Shen HH, Cao F, Xie LY, Zhu GL, Sam NB, Wang DG, Pan HF. Therapeutic potential of enhancer of zeste homolog 2 in autoimmune diseases. Expert Opin Ther Targets 2019;23:1015-30. [PMID: 31747802 DOI: 10.1080/14728222.2019.1696309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Hu P, Dong ZS, Zheng S, Guan X, Zhang L, Li L, Liu Z. The effects of miR-26b-5p on fibroblast-like synovial cells in rheumatoid arthritis (RA-FLS) via targeting EZH2. Tissue Cell 2021;72:101591. [PMID: 34325277 DOI: 10.1016/j.tice.2021.101591] [Reference Citation Analysis]
2 Claringbould A, Zaugg JB. Enhancers in disease: molecular basis and emerging treatment strategies. Trends Mol Med 2021;27:1060-73. [PMID: 34420874 DOI: 10.1016/j.molmed.2021.07.012] [Reference Citation Analysis]
3 Zhou J, Yang Y, Wang YL, Zhao Y, Ye WJ, Deng SY, Lang JY, Lu S. Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease. World J Gastroenterol 2021; 27(22): 3073-3084 [PMID: 34168409 DOI: 10.3748/wjg.v27.i22.3073] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021;6:201. [PMID: 34054126 DOI: 10.1038/s41392-021-00572-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]